What is Chemsex?

Epidemiology, Harms & Impacts

Gary Whitlock, MD, PhD

Consultant Physician HIV and Sexual Health Service Director, 56 Dean Street Clinic Chelsea & Westminster Hospital NHS Foundation Trust London, UK





This activity is jointly provided by Physicians' Research Network and the Medical Society of the State of New York.

Disclosures

I have received speaker and advisory board fees from ViiV & GSK





Objectives

- Substance use
- Chemsex
 - Definition/Terminology
 - 3 main drugs
 - Prevalence
 - Impacts
- Harm reduction

Substance Use

Substance use

- Drug use is common
- Pattern & context varies
 - Geographically
 - Intermittent v. regular
 - With/without sex
 - Licit/illicit/borderline

Substance use

- 'All' drug use 2x GBMSM* cf. gen pop
- Substance use disorder (SUD) 2.5x

*GBMSM = gay and bisexual men who have sex with men

Courtesy of Professor Adam Bourne





Figure 1. Prevalence of Substance Use and Substance Use Disorders among Gay or Bisexual Men as Compared with Heterosexual Men in the United States, 2017–2019.

Compton & Jones. Substance use among men who have sex with men. NEJM (2021) 385:352-6

Substance use: Genito-urinary medicine (GUM) clinic



Scrivener et al. *Recreational drug use among GUM attendees*. BASHH conference (2013)

Chemsex

Sexual health

Gay men warned on risks of 'chemsex'

First British study of 'chemsex' reveals gay men taking serious risks with their health and with HIV after using drugs

Denis Campbell

Tuesday 8 April 2014 21.02 BST





in gay cultural, social and sexual networks.' Photograph: Dosfotos/PYMCA/Rex

C

ay men are suffering serious harm and are in danger of spreading HIV by having unprotected sex while under the influence of illegal drugs, the

Chemsex

World Report

High-risk drug practices tighten grip on London gay scene

Use of crystal methamphetamine is on the rise in London's gay scene, putting men who have sex with men at higher risk of infections. Tony Kirby and Michelle Thornber-Dunwell report.

London's 24-hour gay scene is world famous, with clubbing that goes on all weekend and beyond. Many of London's drug-using men who have sex with men (MSM), and also lesbians, and their heterosexual male and female friends often congregate at post-club parties known as chillouts where drug-taking continues until drugs, money, energy, or all including crystal meth use, putting them at risk of infection with HIV, hepatitis C (HCV), and a range of other bloodborne and sexually transmitted infections (STIs). This trend is concerning since, in 2011, there was a record high 3010 new HIV infections in MSM in the UK, of which 1296 were in London. At the 56 Dean Street Clinic in Soho, London, 511 new cases of HIV lesbian, gay, bisexual, and transgender health and wellbeing charity. This includes managing the UK National Health Service (NHS) partnership clinics: the Club Drug Clinic at Chelsea and Westminster Hospital (funded by the Central and North West London NHS Foundation Trust) and the CODE Clinic at 56 Dean Street (part of the Chelsea and Westminster NHS For more on the 56 Dean Street Clinic see www.chelwest.nhs. uk/56deanstreet/

For more on the Club Drug Clinic see http://www.clubdrugdinic. com/

For more on the CODE Clinic see http://www.code-clinic.co.uk/

Chemsex definition

- Sexualised drug use (SDU) Use of drugs during sex
- Chemsex

Use of specific drugs with <u>specific intention</u> to shape the intensity/longevity/diversity of sex

• Slamsex

Injection of chemsex drugs

	Street names	Common routes of ingestion	Pharmacological properties	
Most commonly rep	orted, or classic, chemsex drug	s		
Methamphetamine	Christina, crystal, crystal meth, ice, meth, Tina	Smoked, snorted, injected (intravenously or anally), or inserted into urethra	Stimulant	Most commonly
GHB and GBL	G, Gina, G water, liquid ecstasy	Swallowed	Depressant	reported chemsex
Mephedrone	Bath salts, drone, Mcat, meow meow, 4-MMC	Smoked, snorted, injected (intravenously or intramuscularly), or swallowed	Stimulant	drugs
Other drugs also con	nsidered part of the chemsex sc	ene in some regions		
Ketamine	K, special K, vitamin K	Smoked or snorted	Depressant, dissociative	Other drugs part of
MDMA	E, ecstasy, Mandy, Molly, XTC	Swallowed	Stimulant	the chemsex
Cocaine	Coca, coke, crack, snow, stash	Smoked or snorted	Stimulant	scene in some
Substances commor	nly used alongside, but not typ	ically constituting, chemsex dru	ıgs	regions
Alkyl nitrites	Bolt, poppers, rush	Snorted	Vasodilator	
Cannabis or marijuana	420, grass, hash, herb, pot, weed	Smoked or swallowed	Cannabimimetic	Drugs commonly used alongside
Sildenafil, tadalafil, and vardenafil	Viagra (brand name), Cialis (brand name), Levitra (brand name)	Swallowed	Vasodilator	chemsex
HB=γ-hydroxybutyrate	e. GBL=γ-butyrolactone. MDMA=3,	4-methylenedioxymethamphetami	ne.	

Short et al. *HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men*. Lancet HIV (2022) 9(10): e717-e725

Meaning and language

Terms used by professions

- Chemsex
- Party and play (PnP)
- Sexualised drug use

Other terms used by gay men

- High and horny (HnH)
- M Play
- T Play
- Chemplay
- Wired play
- Chilling




M = *mephedrone*; *T* = 'tina', crystal methamphetamine

Courtesy of Professor Adam Bourne

Crystal methamphetamine

PHYSIOLOGICAL / BEHAVIOURAL EFFECTS OF CRYSTAL METHAMPHETAMINE



Faculty of Addictions Psychiatry, Faculty Report 2014; Rusyniak DE. Neurol Clin 2011;29(3):641-655; Cruickshank C & Dyer K. Addiction 2009;104:1085-1099

Crystal methamphetamine


CRYSTAL METHAMPHETAMINE

Alternative/street names	Crystal, Tina, Meth
Route of administration	Intravenously, oral ingestion, smoke, insufflation, rectal insertion,
Bioavailability (oral administration)	67-80%
Metabolism	CYP2D6; other non-CYP pathways (minor)
Half-life	~12 hours
Mechanism of action	Increases neuronal release of monoamines. Indirect agonist at dopamine, noradrenaline and serotonin receptors
Interaction potential	Moderate (RTV inhibition of CYP2D6) Weak (COBI inhibition of CYP2D6)
Long-term effect	Depletes the brain's stores of dopamine. Damages dopamine and serotonin nerve terminals. Repeat dosing leads to neuroadaptation and neurotoxicity. Damage to dopamine neurones in the nigrostriatal pathway may increase risk of developing Parkinson's disease in later life

Bracchi M et al. AIDS 2015;29:1585-1592; Cruickshank C & Dyer K. Addiction 2009;104:1085-1099; Rusyniak DE. Neurol Clin 2011;29(3):641-655

Mephedrone

PHYSIOLOGICAL / BEHAVIOURAL EFFECTS OF MEPHEDRONE



Faculty of Addictions Psychiatry, Faculty Report 2014; Bowden-Jones O. The Psychiatrist 2013;37:185-187; Dybdal-Hargreaves N et al. Euro J Pharmacol 2013;714:32-40

Mephedrone

MEPHEDRONE

Alternative/street names	meow meow		
Route of administration	Intravenously, Oral ingestion, insufflation (most common), rectal insertion (dissolved or as gel forms),		
Bioavailability (oral administration)) 10%		
Metabolism	CYP2D6; NADPH-dependent enzymes (minor)		
Half-life	30 minutes – 1.5 hours		
Mechanism of action	Inhibits uptake of serotonin and dopamine (thought to have preference for serotonin)		
Interaction potential	Moderate (RTV inhibition of CYP2D6), Weak (COBI inhibition of CYP2D6)		
Long-term effect	Not known		


Bracchi M et al. AIDS 2015;29:1585-1592; Dybdal-Hargreaves N et al. Euro J Pharmacol 2013;714:32-40; Wood D & Dargan P. Prog Neuro-Psychpharmacol Biol Psy 2012;39:227-233

GHB/GBL

gamma-hydroxybutyric acid/ gamma-Butyrolactone

GHB/GBL

PHYSIOLOGICAL / BEHAVIOURAL EFFECTS OF GHB / GBL



Faculty of Addictions Psychiatry, Faculty Report 2014; Bowden-Jones O. The Psychiatrist 2013;37:185-87

GHB/GBL

GHB / GBL / 1,4 GD

Alternative/street names	G, Gina, liquid E		
Route of administration	n Oral ingestion (liquid), rarely Intravenously		
Bioavailability (oral administration)	1) 10GHB: 59-65% GBL: 85%		
Metabolism	GHB: GHB-DH and SSA-DHGBL: lactonase 1,4 BD: alcohol DH and aldehyde DH		
Half-life	GHB: 20-60 minutes (GLB and 1,4 BD are rapidly converted to GHB)		
Mechanism of action	Binds to GABA (B) receptors		
Interaction potential	Not known		
Long-term effect	Not known		

Bracchi M et al. AIDS 2015;29:1585-1592; Busardo F & Jones A. Curr Neuropharmacol 2015;13:47-70

Chemsex: prevalence

Global prevalence



Global prevalence



Global prevalence, HIV+ GBMSM

- <u>UK</u>
 - Positive voices, 2014, past year
 - 29.5% chemsex
 - 10.1% slamsex
- <u>Spain</u>
 - 22 Madrid hospitals, 2017
 - 29.1% SDU
 - 4.6% slamsex

Pufall et al. Sexualised drug use ('chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men. HIV Medicine (2018) 19: 261-270

Gonzalez-Baeza et al. Sexualised drug use (chemsex) is associated with high-risk sexual behaviours and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 Study. AIDS Patient Care STDs (2018) 32(3): 112-118

Chemsex: impacts

Chemsex impacts

- Prolonged chemsex sessions
 = mucosally traumatic & condomless sex
- Injecting drug use

Risks

- STI, bacterial/viral
- Enteric infections
- MPX?

Pufall et al. Sexualized drug use ('chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men. HIV Medicine (2018) 19:261-270

Thornhill et al. *Monkeypox virus infection in humans across 16 countries – April-June 2022.* NEJM (2022) 387:679-691

Chemsex impacts

- Meta-analyses:
 - Higher risk of
 - Condomless sex
 - STI, within 3/12
 - Living with diagnosed HIV

Maxwell et al. *Chemsex behaviours among men who have sex with men: A systematic review of the literature.* International Journal of Drug Policy (2019) 63: 74-89

Nevendorff et al. *Prevalence of sexualised drug use and risk of HIV among sexually active MSM in East and South Asian countries: systematic review and meta-analysis.* Journal of the International AIDS Society (2023) 26.1; e26054

Chemsex impacts

- 'Syndemic of inequalities'
 - Mental health
 - Sexual health
 - Substance use

 https://neuropsychiatry-hiv.com/en-2021-mark-pakianathan/

Pakianathan et al. *Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with me attending sexual health clinics.* HIV Medicine (2018) 19.7: 485-490

Chems4EU

Chems4EU

- <u>Aim</u>
 - Prevalence, chemsex in HIV+ GBMSM
 - Attending HIV services
 - UK, Spain, Italy, Greece
- <u>2^{ary} aim</u>: measure
 - Sexual behaviour/STI
 - Impacts, chemsex
 - Uptake, chemsex services

Whitlock et al. *Chems4EU: chemsex use and its impact across four European countries in HIV-positive men who have sex with men attending HIV services*. HIV Medicine (2021) 22: 944-957

Chems4EU

- <u>N = 1589</u>
 - In last 12 months
 - 44.6% rec drug use
 - 24.0% chemsex
 - 6.5% slamsex
- Rec drug use/chemsex
 - UK>Spain>Greece>Italy
 - Patterns differ

Whitlock et al. *Chems4EU: chemsex use and its impact across four European countries in HIV-positive men who have sex with men attending HIV services*. HIV Medicine (2021) 22: 944-957

	All	UK	Spain	Greece	Italy
(b) Self-reported cher	msex use ($N = 382$)				
\frown	382	168	113	82	19
GHB/GBL					
Yes	268 (70.2)	117 (69.6)	84 (74.3)	55 (67.1)	12 (63.2)
No	50 (13.1)	23 (13.7)	8 (7.1)	19 (23.2)	0 (0)
Don't know	7 (1.8)	0 (0)	6 (5.3)	1 (1.2)	0 (0)
Blank	57 (14.9)	28 (16.7)	15 (13.3)	7 (8.5)	7 (36.8)
Crystal methampheta	amine				
Yes	256 (67.0)	125 (74.4)	80 (70.8)	47 (57.3)	4 (21.1)
No	56 (14.7)	23 (13.7)	8 (7.1)	24 (29.3)	1 (5.3)
Don't know	3 (0.8)	0 (0)	3 (2.7)	0 (0)	0 (0)
Blank	67 (17.5)	20 (11.9)	22 (19.5)	11 (13.4)	14 (73.7)
Cocaine					
Yes	227 (59.4)	89 (53.0)	78 (69.0)	45 (54.9)	15 (78.9)
No	84 (22.0)	45 (26.8)	12 (10.6)	27 (32.9)	0 (0)
Don't know	7 (1.8)	0 (0)	7 (6.2)	0 (0)	0 (0)
Blank	64 (16.8)	34 (20.2)	16 (14.2)	10 (12.2)	4 (21.1)
Mephedrone					
Yes	185 (48.4)	78 (46.4)	64 (56.6)	39 (47.6)	4 (21.1)
No	99 (25.9)	50 (29.8)	18 (15.9)	31 (37.8)	0 (0)
Don't know	4 (1.0)	0 (0)	4 (3.5)	0 (0)	0 (0)
Blank	94 (24.6)	40 (23.8)	27 (23.9)	12 (14.6)	15 (78.9)
Ketamine					
Yes	122 (31.9)	40 (23.8)	69 (61.1)	11 (13.4)	2 (10.5)
No	134 (35.1)	69 (41.1)	15 (13.3)	50 (61.0)	0 (0)
Don't know	3 (0.8)	0 (0)	2 (1.8)	1 (1.2)	0 (0)
Blank	123 (32.2)	59 (35.1)	27 (23.9)	20 (24.4)	17 (89.5)

Abbreviations: GHB, gamma-hydroxybutyrate; GBL, gamma-butyrolactone.

Chems4EU: impacts

- <u>382 chemsex in last 12 months</u>
 - 40.6% unwanted side-effects
 - 7.1% emergency medical care
 - 7.3% drug overdose
 - Negatively impacted on
 - Work 25.1%
 - Friends/family 24.3%
 - Intimate relationships 28.3%

Whitlock et al. *Chems4EU: chemsex use and its impact across four European countries in HIV-positive men who have sex with men attending HIV services*. HIV Medicine (2021) 22: 944-957

Associated factors

- Factors assoc with chems use in HIV+ GBMSM in England
- Univariable analysis (OR):
 - London clinic (2.14)
 - Missing 3+ ART (3.08)
 - 10+ sex partners (8.34)
 - Group sex (6.81)
 - Fisting (4.99)
 - Bacterial STI in last y (3.76)
 - Unsure/unhappy with sex life (2.21)

Whitlock et al. *Factors associated with chemsex in HIV+ MSM attending English HIV services*. BHIVA/BASHH 5th joint conference (2021): P77

Chems4EU: impacts

	All	UK	Spain	Greece	Italy
Access professional ser	rvices in relation to your c	hemsex ^b			
Yes	57 (14.9)	32 (19.0)	18 (15.9)	6 (7.3)	1 (5.3)
No	310 (81.2)	131 (78.0)	89 (78.8)	74 (90.2)	16 (84.2)
Don't know	8 (2.1)	1 (0.6)	3 (2.7)	2 (2.4)	2 (10.5)
Blank	7 (1.8)	4 (2.4)	3 (2.7)	0 (0)	0 (0)
If yes, did the service n	neet your needs?				
Yes	38 (66.7)	20 (62.5)	13 (72.2)	4 (66.7)	1 (100)
No	9 (15.8)	5 (15.6)	2 (11.1)	2 (33.3)	0 (0)
Don't know	6 (10.5)	3 (9.4)	3 (16.7)	0 (0)	0 (0)
Blank	4 (7.0)	4 (12.5)	0 (0)	0 (0)	0 (0)

Whitlock et al. *Chems4EU: chemsex use and its impact across four European countries in HIV-positive men who have sex with men attending HIV services*. HIV Medicine (2021) 22: 944-957

Chems impacts

- Acute intoxication assoc. amphetamine
 - Oct 18 Oct 20
 - HIV+, ED, Hospital Clinic, BCN
 - N=170
 - 28.2% severe intoxication (admission >=6h)
 - 12 (7.1%) ITU
 - 2 (1%) died

Perello et al. *Amphetamine-related implications in people living with HIV: an observational study in an Emergency Department in Barcelona (Spain) from 2018 to 2020*. HIV Medicine (2023) 24: 260-266

TABLE 2 Unadjusted and adjusted analyses of factors associated with severe acute amphetamine intoxication in 170 people living with HIV

	Unadjusted		Adjusted	
Characteristic	OR(C.I.95%)	<i>p</i> -value	OR(C.I.95%)	<i>p</i> -value
Age	1.01 (0.72–1.93)	0.7		
Mental disorder	1.03 (0.52–2.01)	0.55		
IgG antibodies hepatitis C	2.14 (0.74–6.12)	0.18		
CD4 cell count	0.87 (0.44–1.73)			
>350 cells		0.71		
RNA HIV-1 <20 copies	1.17 (0.55–2.46)	0.38		
Ritonavir/cobicistat-based ART	0.75 (0.86–15.3)	0.05		
Suicide attempt	4.6 (1.14–14.9)	0.01	4.6 (1.8–11.6)	< 0.01
Methamphetamine	1			
Amphetamine	1.47 (0.23–2.34)	0.48		
MMDA	0.98 (1.12-4.52)			
Injected drug use	3.99 (1.2–13.28)	0.03	2.56 (0.64–10.21)	0.18
Polysubstance use	1.48 (0.62–3.54)	0.44		
Agitation, anxiety, chest pain	1		1	
Psychosis	8.7 (2.61–38.73)	<0.01	5.86 (2.27–15.2)	< 0.01
Altered level of consciousness	15.1 (3.64–62.4)		6.58 (2.37–18.9)	
Ritonavir/cobicistat-based ART	0.75 (0.86–15.3)	0.05		

Abbreviations: ART, antiretroviral therapy; IgG, immunoglobulin G; MMDA, 3-methoxy-4,5 methylenedioxyamphetamine; RNA, ribonucleic acid. Data are presented as odds ratio (95% confidence interval) unless otherwise indicated.

Chems & HIV

- Chems4EU
 - Missed ART doses
 - 3+ in last 14/7 (5.5% v 2.3%; aOR 2.54)
- REACH, London, UK (2014-15)
 - Sub-optimal clinic attendance
 - aOR 1.71

Whitlock et al. *Chems4EU: chemsex use and its impact across four European countries in HIV-positive men who have sex with men attending HIV services*. HIV Medicine (2021) 22: 944-957

Howarth et al. *The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London.* HIV Medicine (2021) 22: 641-649

Chems & ART

Drug	Metabolism	Interaction Potential		Signs of Toxicity	Recommendations with	
		Cobicistat (Cobi) Ritonavir (RTV) Lenacapavir (LEN)	BIC, CAB, DOR, DTG, FTR, MVC, RAL, RPV, NRTIs		cobicistat, ritonavir or lenacapavir containing regimens	
Benzodiazepines:	CYP3A4	High (Cobi, RTV)	Low	 Drowsiness 	 Contraindicated with cobicistat 	
Midazolam, Triazolam		Moderate (LEN)		 Disorientation 	and ritonavir.	
Benzodiazepines:	CYP3A4	High (Cobi, RTV)	Low	 Drowsiness 	 Caution – use lower dose of 	
Others		Moderate (LEN)		 Disorientation 	benzodiazepine.	
Cocaine	CYP3A4 (minor)	Low-moderate	Low	Tremors	Clinical relevance unknown.	
			(Note, caution with FTR	 Paranoia 	 Inform users of signs of toxicity. 	
			and RPV due to known	 Seizures 	10.00	
			risk of QT prolongation with cocaine)	 Headache 		
			with cocaine)	 Hyperthermia 		
Ecstasy (MDMA)	CYP2D6	Limited CYP2D6	Low	 Hypertension 	 Avoid if possible. 	
		inhibition but small PK changes could be		 Seizures 	 If unavoidable with cobicistat or 	
		significant due to non-		 Hyperthermia 	ritonavir, start with ~25-50% of	
		linear PK (Cobi, RTV)		 Arrhythmia 	the usual amount of ecstasy.	
		Low (LEN)		 Tachycardia 	 Inform users of signs of toxicity. 	
				 Teeth grinding 		
GHB	GHB	Unknown. Caution	Low	 Seizures 	 Use with caution. 	
	dehydrogenase	due to GHB narrow		 Bradycardia 	 Use lower dose. 	
	CYP?	therapeutic index		Respiratory depression	 Inform users of signs of toxicity. 	
Ketamine	CYP3A4	High (Cobi, RTV)	Low	 Respiratory depression 	 Avoid if possible. 	
		Moderate (LEN)		 Hallucinations 	 If unavoidable with cobicistat or ritonavir, start with ~33-50% of the usual amount of ketamine. 	
Mephedrone	CYP2D6	Limited CYP2D6	Low	 Tachycardia 	 Use lower dose with cobicistat 	
ner etter som etter at den etter som ette		inhibition (Cobi, RTV)		 Agitation 	and ritonavir.	
		Low (LEN)			 Inform users of signs of toxicity. 	
Methamphetamine	CYP2D6	Limited CYP2D6	Low	 Hypertension 	 Avoid if possible. 	
2		inhibition but small PK changes could be		 Seizures 	 If unavoidable with cobicistat or 	
		significant due to non-		 Hyperthermia 	ritonavir, start with ~25-50% of	
		linear PK (Cobi, RTV)		 Arrhythmia 	the usual amount of	
		Low /LENI)		 Tachycardia 	methamphetamine.	
		Low (LEN)		 Teeth grinding 	 Inform users of signs of toxicity. 	
Poppers (nitrites)	Non-CYP	Low	Low	 Dizziness 	 Inform users of signs of toxicity. 	
	mediated			 Hypotension 		
Sildenafil	CYP3A4	High (Cobi, RTV)	Low	 Chest pain 	Use lower dose:	
Tadalafil		Moderate (LENI)		Nausea	Sildenafil – 25 mg in 48 h	
Vardenafil		Moderate (LEN)		 Arrhythmia 	Tadalafil – 10 mg in 72 h Vardenafil – 2.5 mg in 72 h (5 mg in 24 h with lanacanavir)	
					(5 mg in 24 h with lenacapav	

www.hiv-druginteractions.org/prescribing_resources/hiv-guidance-chemsex


Harm reduction

Obstacles

- Not a problem in your population?
- You forget to ask
 - Proformas; ?prompts
- Panic!
 - Your own knowledge
 - Drugs; effects; potential problems
 - Authenticity
 - Terminology
 - Local use which ones are out there




Chems impacts



Scrivener et al. Recreational drug use among GUM attendees. BASHH conference (2013)

Asking about substance use



Asking about substance use



Harm reduction




Figure: Proposed scheme of harm-reduction strategies for chemsex

ART=antiretroviral therapy. **HAV**=hepatitis A virus. HBV=hepatitis B virus. HPV=human papillomavirus. **IEC**=information education and communication. **NSP**=needle and syringe programmes. **PEP**=post-exposure prophylaxis. **PrEP**=pre-exposure prophylaxis. STI=sexually transmitted infection. VCT=voluntary counselling and testing.

Strong et al. *HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men.* Lancet HIV (2022) 9(10): e717-e725

What do we offer

- Brief discussion in consultation
- Referral to counselling team:
 - Assessment & therapeutic intervention
 - Motivation interviewing (risk reduction)
 - CBT (behavioural therapy)
 - Brief psychodynamic therapy
- Refrral to addiction services

Chemsex support at 56DS

- HIV/GUM clinic
 - Brief MI (motivational interviewing)
 - Health advisor team
- Substance use support: <u>CODE</u>
 - One-to-one with counsellor
 - Online resources




- Risk reduction advice
- <u>Club drug clinic: clinical intervention</u>



Walk-in 1 to 1 chat Here to help, not to judge.

 Tuesday 5 - 7pm
 Thursday 1 - 4pm
 1st & 3rd Saturday of the month 1 - 3pm

Location



Welcoming space



Care plan

Carl	Plan.	ChemSe	ChemSex				
DEAN TREET		enemoe	Name			DATE	
Part 1: What is	your goal?	Abstinence?	Red	uced use?	Controlled us	e?	Safer use?
Te	keep your go	als small, realistic	and achieval	ole, and to gain a	feeling of accomp	blishment	
Try committing to	a period of ab	stinence (with our	support for):	1 month 2	months 3 r	nonths	4 months
How confident a	27 - 27.42		support lory,				
C							
Not confident	1 2	2 3 4	4 5	6 7	8 9	10	Confident
		ce score is less t			7. 7.	77.77.	
Contraction			han 7? Re-		7. 7.	77.77.	
ls y	our confiden 1 week	ce score is less t 2 weel	han 7? Re-	adjust your goal 3 weeks	to improve you 1 month	confidence	


Care plan

Home alone Name others	
	u do differently next time you feel a craving/trigger?
What suppor	ive person can you call if you feel a craving/trigger?
What enjoya	ple/productive things can you plan into your upcoming free time, to keep yourself occupied?
	se to abstain from sex, as well as sex apps, during this vulnerable time, as it might trigger you is unlikely, or unattractive to you, what might you have to do differently to enjoy sober sex?

Needle/syringe programmes



Needle/syringe programmes





Clinical intervention

Guidelines on when to call an ambulance to take recreational drug users to A&E

Call an ambulance if ANY of the following are present:

1. AVPU assessment graded as either P or U A=Alert V=Responds to voice i.e. talking to P= Responds to painful stimuli only (e.g. pressure across a finger nail) U=Unconscious

2. Chest pain similar to a 'heart attack' (i.e. like a pressure on the chest, like a band around the chest).

3. Any history of seizures (i.e. a convulsion similar to an epileptic fit) during this episode

- 4. More than 2 'poisoned clubbers' per 'club medic'
- 5. Temperature >38°C not settling after 15 minutes of rest OR a temperature >40°C at any time

6. Heart rate >140 beats per minute not settling within 15 minutes

7. Blood pressure Systolic <90 or >180, Diastolic >110 on 2 readings 5 minutes apart

8. Confusion, significant agitation (e.g. pacing around the room) or significant aggression not settling within 15 minutes

9. Any concerns on behalf of the medical personnel involved

10. IF IN DOUBT CALL AN AMBULANCE

[©]Guy's & St Thomas' Poisons Unit

Guidance for paramedics in Clubs...

Crystal meth psychosis

- Presents with apparent drug-induced psychosis:
 - Reassure that they are safe
 - Assess if patient is a risk to:
 - Themselves
 - Others
 - Refer to A&E (ER) if appropriate
 - Liaison psychiatry

Management: G detox

- If patients are using G:
 - If using daily for 4 consecutive days or more
 - Do not stop without medical advice
 - Immediately to A&E (ER) if no more supply
 - Call ahead to A&E (ER) to alert staff about G withdrawal symptoms

What can you do?

- Be aware of recreational drugs, their short- and longterm effects and risks
- Be aware of potential drug-drug interactions between antiretrovirals and drugs
- Provide safety advice on possible harm and sources of information
- Agree referral pathways into appropriate services



Evaluation

Outcomes

Web-Based Harm Reduction Intervention for Chemsex in Men Who Have Sex With Men: Randomized Controlled Trial

Monitoring Editor: Amaryllis Mavragani

Reviewed by Steven John and Zhao Ni

Edmond Pui Hang Choi, PhD,²¹ Kitty Wai Ying Choi, MSocSc,^{1,2} Chanchan Wu, MSc,¹ Pui Hing Chau, PhD,¹ Jojo Yan Yan Kwok, PhD,¹ William Chi Wai Wong, MD,³ and Eric Pui Fung Chow, PhD^{4,5,6}

• Starting to see evaluations

- Randomised controlled trial
 - Hong Kong
- Lower PrEP use
- Intervention promoted testing and condom use

Acknowledgements

- Prof Adam Bourne, La Trobe University, Melbourne, Australia
- Team at 56 Dean Street, London

Any questions?

Thank You for Your Attendance! Please visit us at:

www.prn.org